Lexicon Pharmaceuticals, Inc. - Common Stock (LXRX)
0.3360
+0.0112 (3.45%)
Lexicon Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapies to treat various diseases, including rare genetic disorders and chronic conditions
Through its cutting-edge research and development initiatives, Lexicon aims to leverage its proprietary drug discovery platform to identify and advance new treatment options that can significantly improve patient outcomes. The company is committed to making a positive impact on healthcare by addressing unmet medical needs through its portfolio of potential therapeutic candidates.
Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from its PROGRESS Phase 2b study evaluating pilavapadin.
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025.
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December.
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
